Gene Transfer with SRP-6004 for Limb-Girdle Muscular Dystrophy
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you require chronic drug treatment that the investigator believes poses a risk for gene transfer, it might be a concern.
What data supports the effectiveness of the treatment SRP-6004 for Limb-Girdle Muscular Dystrophy?
Is SRP-6004 gene therapy safe for humans?
Research on similar gene therapies using adeno-associated virus (AAV) vectors, like those for other muscular dystrophies, shows they are generally well-tolerated with no significant toxicity observed in animal studies. However, there are concerns about immune responses, so safety measures are important to minimize risks.16789
How does the treatment SRP-6004 differ from other treatments for limb-girdle muscular dystrophy?
SRP-6004 is unique because it uses gene transfer therapy to deliver a functional version of the γ-sarcoglycan gene directly into muscle cells, aiming to correct the underlying genetic defect causing limb-girdle muscular dystrophy. This approach is different from traditional treatments as it targets the root cause of the disease rather than just managing symptoms.1251011
What is the purpose of this trial?
This trial is testing the safety of a medicine called SRP-6004, given through a vein, in people who can walk but have a specific type of muscular dystrophy (LGMD2B/R2).
Research Team
Medical Director
Principal Investigator
Sarepta Therapeutics, Inc.
Eligibility Criteria
This trial is for ambulatory individuals with Limb Girdle Muscular Dystrophy, Type 2B/R2. Participants must have specific genetic mutations related to the condition, be able to perform motor tests, and not have high levels of certain antibodies. They can't join if they've had recent gene therapy or other investigational treatments, significant health issues, or need chronic drug treatment that could pose risks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single IV infusion of SRP-6004 on Day 1
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- SRP-6004
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sarepta Therapeutics, Inc.
Lead Sponsor